Results 111 to 120 of about 396 (132)

Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency

The Journal of Clinical Endocrinology & Metabolism
Abstract Context Once-weekly somapacitan is approved for treating adults with growth hormone deficiency. Phase 3 trials support its noninferiority to daily growth hormone (GH); however, its effect on comprehensive metabolic outcome, including muscle strength, during routine care, remains ...
Yuka Oi-Yo, Shin Urai, Masaaki Yamamoto, Seiji Tomofuji, Yuka Ohmachi, Yuriko Sasaki, Hironori Bando, Michiko Takahashi, Genzo Iguchi, Risa Harada, Yoshitada Sakai, Hidenori Fukuoka   +11 more
openaire   +2 more sources

Effects of somapacitan on glucose metabolism in adults with GH deficiency

Endocrine Abstracts, 2022
Gudmundur Johannsson, Biller Beverly MK, Hidenori Fukuoka, Ken Ho, Rasmussen Michael Hojby, Navid Nedjatian, Claus Svaerke, Yuen Kevin CJ, Yutaka Takahashi   +8 more
openaire   +1 more source

Administration study of somapacitan, a long-acting growth hormone derivative, in horse for doping control purpose

Growth Hormone & IGF Research
Somapacitan is the second generation of recombinant human growth hormone (rhGH) medication that retains the pharmacological effects of rhGH but exhibits a longer duration of action due to its reversible albumin-binding in the body. In general, the use of all recombinant growth hormone (rGH) analogues is banned by the human and animal sports regulatory ...
Yoshibumi, Shimizu, Michiko, Sugai-Bannai, Haruka, Tanabe, Kazunobu, Saito, Hiroki, Ito, Hirotaka, Tokushige, Kazuhiro, Kamiya, Misato, Hirano-Kodaira, Masayuki, Yamada, Gary Ngai-Wa, Leung   +9 more
openaire   +2 more sources

Rare adverse event of treatment with somapacitan after switch from somatotropine

Endocrine Abstracts, 2023
Matej Rakusa, Andrej Janez, Mojca Jensterle   +2 more
openaire   +1 more source

Absorption, Metabolism and Excretion of Once-Weekly Somapacitan, a Long-Acting Growth Hormone Derivative, After Single Subcutaneous Dosing in Human Subjects

European Journal of Pharmaceutical Sciences, 2021
Birgitte Bentz Damholt, Michael Højby Rasmussen   +1 more
exaly  

Structure Identification of Circulating Metabolites From Somapacitan, a Long-Acting Growth Hormone Derivative, and Pharmacokinetics After Single and Multiple Subcutaneous Dosing in Rats

European Journal of Pharmaceutical Sciences, 2022
Peter Thygesen
exaly  

Orphan designation: Somapacitan, Treatment of growth hormone deficiency

Case Medical Research, 2018
openaire   +2 more sources

Weekly Somapacitan Had No Adverse Effects on Glucose Metabolism in Adults With Growth Hormone Deficiency

Pituitary, 2023
Hidenori Fukuoka, Navid Nedjatian, Yutaka Takahashi   +2 more
exaly  

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.

Journal of Clinical Endocrinology and Metabolism, 2020
Kei Takasawa, Tadej Battelino, Michael Højby Rasmussen   +2 more
exaly  

Somapacitan - Behebt den Mangel an Wachstumhormon

Österreichische Apothekerzeitung, 2022
openaire   +1 more source